Key takeaways
- UPCR 0.8-1.5 g/g proteinuria threshold in representative commercial and Part D prior-authorization policy, alongside eGFR ≥30 and RAS-blockade step-through
- $60K-70K vs $80K-100K budesonide (Tarpeyo) vs sparsentan (Filspari) annual WAC, the two established price anchors in a five-agent, PA-gated class
- $100K-175K ICER 2026 assessment modeled cost per QALY range, the value ceiling any new entrant's price is measured against
- No disclosed rebate figure for any of the five FDA-approved IgAN agents; access here is a PA-qualification market, not a negotiated net-price market
US IgAN pricing strategy has no rebate table to model because access is decided by a shared prior-authorization gate, not a payer negotiation.
Budesonide (Tarpeyo), sparsentan (Filspari), atrasentan (Vanrafia), iptacopan (Fabhalta) and sibeprenlimab (Voyxact) are all patient-administered and route through the Medicare Part D or commercial pharmacy benefit. Representative commercial and Part D policies condition coverage on biopsy-confirmed primary IgAN, an eGFR floor of roughly 30 mL/min/1.73m2, a proteinuria threshold typically UPCR 0.8-1.5 g/g, and a documented trial of optimized RAS blockade, increasingly alongside an SGLT2 inhibitor, before any disease-specific agent is covered. Sparsentan carries an added REMS for hepatotoxicity monitoring, enrollment friction its four competitors do not carry. Because every agent clears the same gate, the pricing lever that matters in this market is qualifying for the gate faster and more cleanly than the four incumbents already through it, not out-discounting them on net price.
This is why a conventional rebate-and-GTN waterfall does not exist for IgAN in the way it does for a crowded specialty class with active formulary competition. Budesonide's WAC runs roughly $60,000-70,000 per year and sparsentan's roughly $80,000-100,000, and the ICER 2026 assessment models cost per QALY in the $100,000-175,000 range depending on how eGFR benefit translates to ESKD delay. No disclosed rebate, net-price, or GTN figure exists for any of the five agents in the public or payer-policy record we reviewed. That absence is not a research gap to be filled with an estimate; it is the finding. A prospective entrant's pricing strategy in IgAN is a PA-qualification strategy first, built around confirmatory eGFR-slope evidence and REMS-free administration, with the WAC-to-ICER math as a secondary check rather than a rebate negotiation to be modeled line by line.
US IgAN pricing is decided by prior-authorization qualification, not a rebate table
| Agent | Annual WAC | PA Gate | Added Friction |
|---|---|---|---|
| Tarpeyo (budesonide) | ~$60,000-70,000 | Biopsy; UPCR threshold; eGFR ≥30; RAS-blockade step-through | None; full approval eases coverage vs accelerated-only peers |
| Filspari (sparsentan) | ~$80,000-100,000 | Same shared PA gate; some plans additionally step-edit budesonide | REMS hepatotoxicity enrollment |
| Vanrafia (atrasentan) | Not yet disclosed | Same shared PA gate | REMS-free |
| Fabhalta (iptacopan) | Not yet disclosed | Same shared PA gate | Meningococcal vaccination required |
| Voyxact (sibeprenlimab) | Not yet disclosed | Same shared PA gate | PA criteria still forming; newest approval |
Sources: FDA Drugs@FDA and product labeling; representative commercial and Medicare Part D specialty pharmacy prior-authorization policies (2025-2026); ICER 2026 IgA nephropathy assessment (CTAF review).
What this model answers
Every section answers a named commercial question your team is asking, scoped to your asset.
- Why does US IgAN pricing strategy hinge on prior-authorization qualification rather than a rebate negotiation, and what does that mean for a new entrant's price-setting process? • The shared PA gate across all five FDA-approved agents (biopsy, UPCR, eGFR, RAS-blockade step-through) • why no disclosed rebate or net-price figure exists in this class • the pricing-strategy implication of a PA-first, not rebate-first, market
- How does sparsentan's REMS hepatotoxicity requirement change its competitive position against REMS-free budesonide, atrasentan, iptacopan and sibeprenlimab? • REMS enrollment friction quantified against four REMS-free competitors • the access-speed argument for a REMS-free new entrant • where REMS burden shows up in payer PA turnaround
- What WAC would clear the ICER 2026 assessment's $100,000-175,000 cost-per-QALY range, and how does that compare to budesonide and sparsentan's current pricing? • ICER 2026 IgAN assessment value framing • budesonide and sparsentan WAC benchmarks • the price ceiling a new entrant's confirmatory eGFR-slope evidence would need to clear
What's inside
-
1 · The Binding Constraint 2 pp
- Why PA-gate qualification, not rebate negotiation, decides who competes in US IgAN
- Pressure-tested against the absence of any disclosed rebate figure across all five approved agents
-
2 · Price Ladder — WAC Anchors 3 pp
- Budesonide and sparsentan WAC as the class's two established price points
- Where iptacopan, atrasentan and sibeprenlimab are expected to land
-
3 · The Shared PA Gate 3 pp
- Biopsy, UPCR 0.8-1.5 g/g, eGFR ≥30, RAS-blockade step-through, common to all five agents
- Why PA-qualification speed, not price, is the primary competitive lever
-
4 · REMS Friction Analysis 2 pp
- Sparsentan's hepatotoxicity REMS versus four REMS-free competitors
- Enrollment friction quantified against access-speed benchmarks
-
5 · Value-Based ICER & the $100K-175K Ceiling 3 pp
- The ICER 2026 assessment's cost-per-QALY range
- How confirmatory eGFR-slope evidence changes the value case
-
6 · Net-Price Data Gap Analysis 2 pp
- Why no disclosed rebate or GTN figure exists for any of the five agents
- What this absence means for pricing-strategy assumptions
-
7 · Launch Sequencing & Revenue Scenarios 4 pp
- Sequencing recommendation against four PA-qualified incumbents
- Conservative, base, and aggressive revenue scenarios
-
8 · Client Alignment Questions 2 pp
- The open pricing questions your team must close before a US IgAN launch price is locked
- Structured for an internal pricing committee session
Appendix and source ledger included · 45-minute analyst readout included with delivery
Custom model delivered in 72 hours.
Assess this reportIncluded with every brief
Get Started
Commission this model
AXLRx delivers IgA nephropathy pricing strategy models built for market access and pricing teams navigating a PA-gated, not rebate-negotiated, US access environment. Custom model in 72 hours.
- 1. Submit your requestSpecify your indication, target payer segment, and comparator scope.
- 2. Scoping callAXLRx analyst confirms pricing mechanism assumptions and WTP threshold before building.
- 3. DeliveryResearch-verified pricing model in 72 hours with optional analyst readout.
How AXLRx builds this model
Prepared by MoatRx analysts on the AXLRx commercial consulting engine.
Every AXLRx pricing model is built from primary regulatory and payer-policy sources, not secondary summaries. Where a rebate or net-price figure is not disclosed anywhere in the primary record, the model states that gap explicitly rather than substituting an estimate.
IgA nephropathy US pricing sources: FDA Drugs@FDA and product labeling for approval status, routing and the sparsentan REMS; representative commercial and Medicare Part D specialty pharmacy prior-authorization policies; the ICER 2026 IgA nephropathy assessment and CTAF review.
- Shared PA-gate criteria (biopsy, UPCR, eGFR, RAS-blockade step-through) verified against current commercial and Medicare Part D specialty pharmacy coverage policies
- Budesonide and sparsentan WAC figures and the sparsentan REMS verified against FDA Drugs@FDA and product labeling
- ICER cost-per-QALY range verified against the ICER 2026 IgA nephropathy assessment (CTAF review)
- Absence of a disclosed rebate or net-price figure confirmed across the full primary regulatory and payer-policy record reviewed; no estimate was substituted
Frequently asked questions
Deliverables What formats are included with every model?
Every commissioned Pricing Strategy Model includes an editable 12-sheet Excel model (Price Ladder, PA-Gate Criteria, REMS Friction, Value-Based ICER, Net-Price Gap Analysis, Launch Sequencing, Revenue Scenarios, Sensitivity, Payer Landscape, QC, Sources) and a PDF methodology brief, no PowerPoint deck, since a pricing model is built to be worked in directly, not presented from. An optional 45-minute analyst readout call is included.
Sources Why does this model not include a rebate or net-price figure?
Because none exists in the primary regulatory or payer-policy record for any of the five FDA-approved IgAN agents. AXLRx does not substitute an estimate for a figure that is not disclosed; the model states the gap explicitly and builds the pricing strategy around the PA-qualification gate instead.
Customisation Can I model a specific payer segment or comparator set?
Yes. The intake form captures your indication, target payer segment, comparator class, and WTP threshold. A scoping call confirms scope before research starts. Commission via the intake form to start.